Moderna vs Qiagen
MRNA and QGEN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MRNA and QGEN compare
Qiagen grew revenue faster over the last twelve months (5.7% versus −27.6% for Moderna).
Qiagen keeps more of each dollar of sales as profit, with a net margin of 20.3% compared with −141% at Moderna.
Qiagen scores higher on the StockData Score (10 against 5 for Moderna), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MRNA | QGEN |
|---|---|---|
| Size and price | ||
| Market cap | $88.5B | – |
| Share price | $221.72 | $50.22 |
| Change, 1 year | 798% | 1.1% |
| Change, 5 years | −6.4% | −12.0% |
| Beta (5Y) | 1.11 | 0.69 |
| Employees | 4,700 | 5,700 |
| StockData Score | ||
| Total score | 5 | 10 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 1 | 4 (better) |
| Health score | 3 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 39.7× | – |
| P/B | 13.1× | – |
| FCF yield | −1.4% | – |
| Fair value | $33.24 | – |
| Margin of safety | −567% | – |
| Growth | ||
| Revenue growth (TTM) | −27.6% | 5.7% (better) |
| Revenue growth, 5Y average | 19.3% (better) | 2.2% |
| Net income growth (TTM) | – | 408% |
| EPS growth (TTM) | – | 424% |
| EPS growth, 5Y average | – | 4.9% |
| Profitability | ||
| Gross margin | 23.4% | 62.2% (better) |
| Operating margin | −149% | 22.3% (better) |
| Net margin | −141% | 20.3% (better) |
| FCF margin | −55.8% | 21.7% (better) |
| Return on equity | −39.0% | 11.6% (better) |
| Return on invested capital | −80.9% | 9.9% (better) |
| Financial health | ||
| Debt / equity | 0.09 (better) | 0.44 |
| Net debt / EBITDA | – | 0.84 |
| Interest coverage | – | 14.0× |
| Current ratio | 2.29 | 3.90 (better) |
| Altman Z-score | 12.86 | – |
| Piotroski F-score | 3 | 8 (better) |
| Dividends and buybacks | ||
| Payout ratio | – | 12.8% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 79.9% | 67.4% |
| Held by insiders | 5.6% | 0.00% |
| Insider net buying, 12 months | −$64.6M | – |
| Short interest, % of float | 8.2% | 3.5% |
Go deeper
- MRNA stock overview
- MRNA income statement
- MRNA valuation and score
- QGEN stock overview
- QGEN income statement
- QGEN valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.